Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio and strengthening its branded business. By 2030, the company aims for 70% of its revenue to come from branded products, focusing on dermatology, respiratory, and oncology. A recent deal with AbbVie for its cancer drug ISB 2001 highlights this strategic shift.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ym1bgjE
via IFTTT